Shire buys into regenerative medicine with Pervasis purchase

Article Date: 13/04/2012 10:00
Shire buys into regenerative medicine with Pervasis purchase

Vacancy Search

Quick job search

Advanced Search

Latest News

Novartis' Afinitor extends progression-free survival in NET

Novartis' Afinitor extends progression-free survival in NET

Regeneron/Sanofi drug improves RA symptoms in PhIII trial

Regeneron/Sanofi drug improves RA symptoms in PhIII trial

Boehringer, Eureka in intra-cellular antibodies pact

Boehringer, Eureka in intra-cellular antibodies pact

Could you be the PharmaTimes Marketer of the Year 2015?

Could you be the PharmaTimes Marketer of the Year 2015?

Novartis COPD therapies hit Phase III targets

Novartis COPD therapies hit Phase III targets

Alnylam gains on US orphan status for amyloidosis drug

Alnylam gains on US orphan status for amyloidosis drug

Rumours grow of 'PfizerKline' deal in Q3

Rumours grow of 'PfizerKline' deal in Q3

J&J plans to file 10 potential blockbusters by 2019

J&J plans to file 10 potential blockbusters by 2019

Janssen snaps up autoimmune programme from Novo

Janssen snaps up autoimmune programme from Novo

Astellas' clostridium antibiotic Dificlir cut recurrence, costs

Astellas' clostridium antibiotic Dificlir cut recurrence, costs
more news